Feb. 18, 2009--Orexo and Neopharm Ltd of Israel have signed an exclusive distribution agreement that grants Neopharm rights to market and sell Abstral, Orexo's product for treatment of breakthrough cancer pain, in Israel.
The details can be read here.
No comments:
Post a Comment